-
Company Insights
NewHuawei Pay – Competitor Profile
Huawei Pay was launched in 2016 via a collaboration between payment scheme China UnionPay and smartphone brand Huawei, with the aim of competing in China’s exponentially expanding mobile payments market. Huawei Pay offers a ranges of payment services, including in-app and in-store payments. It offers both NFC payment as well as QR code payments for in-store purchases. To ensure privacy and security for payments, Huawei Pay utilizes tokenization and biometric authentication such as fingerprint recognition. Challenging the dominance of established...
-
Thematic Analysis
NewStrategic Partnerships in Fintech – Thematic Intelligence
Strategic Partnerships in Fintech Thematic Report Overview Strategic partnerships for fintech companies can include traditional vendor relationships, new niche fintech partners, big tech partners, and/or bank-as-a-service of distribution arrangements with firms outside of financial services. The right partnership can deliver overnight scale via access to new markets or customers or neutralize a disintermediating threat.Moreover, working with proven partners and business models for distribution or as a tech partner will be more attractive. The ‘strategic partnerships in fintech’ thematic intelligence report...
-
Macroeconomic Analysis
NewVenezuela PESTLE Insights – A Macroeconomic Outlook Report
Mining, manufacturing and utilities activities contributed 45.9% to the gross value added (GVA) in 2023, followed by wholesale, retail and hotels (24.1%), and construction activities (2.4%), according to GlobalData estimates. According to OPEC, Venezuela has around 303.2 billion barrels of proven crude oil reserves, it produced 716,000 barrels of crude oil per day in 2022.
-
Analyst Opinions
Redefined Households – Consumer TrendSights Analysis, 2023
Redefined Households - Consumer TrendSights Report Overview Redefined Households is a trend in GlobalData's TrendSights framework, under the demographics mega-trends. Household dynamics continue to diversify and change for consumers with external pressures and internal preferences. The diverse nature of households is becoming more common around the globe as inhibitors such as traditional stereotypes and regional barriers are being broken down. This has led to more "global" consumers with greater commonalities than may have been the case historically. Redefined Households Consumer...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Epilepsy Drug Details: Human immunoglobulin (Privigen /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Refractory Multiple Myeloma Drug Details: Afatinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Esophageal Cancer Drug Details: Afatinib dimaleate (Giotrif, Gilotrif,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Low-Grade Glioma Drug Details: Afatinib dimaleate (Giotrif, Gilotrif,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Lymphoma Drug Details: Afatinib dimaleate (Giotrif, Gilotrif, Xovoltib)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Cutaneous Squamous Cell Carcinoma...